体内抑制中性内肽酶1可提高人肿瘤对[177Lu]Lu-PP-F11N的吸收剂量:lumed 0b期研究
这项前瞻性0期研究纳入8例晚期甲状腺髓样癌患者,随机交叉接受两次约1 GBq [177Lu]Lu-PP-F11N输注,比较用与不用含48.6 mg沙库巴曲的Entresto®预处理的效果。预处理未增加毒性,显著提高血液中示踪剂稳定性(p<0.001),肿瘤吸收剂量中位数提高2.6倍(0.74 vs 0.28 Gy/GBq,P=0.03),但胃、肾和骨髓吸收剂量也增加,肿瘤与器官吸收剂量比无显著差异。
要点
- Entresto®预处理未增加毒性,显著提高[177Lu]Lu-PP-F11N在血液中的稳定性(p<0.001)。
- 预处理后肿瘤吸收剂量中位数为0.74 Gy/GBq,未预处理为0.28 Gy/GBq(P=0.03)。
- 胃、肾和骨髓吸收剂量同时增加,肿瘤与器官吸收剂量比无显著差异。
核心结论
- 用Entresto®预处理可使[177Lu]Lu-PP-F11N在体内得到有意义的稳定,并随之提高肿瘤和器官的辐射剂量。
研究设计与样本
- 前瞻性0期研究,纳入8例连续晚期甲状腺髓样癌且近期有生长抑素受体亚型2 PET/CT扫描的患者。
- 患者开放标签、随机交叉接受两次约1 GBq [177Lu]Lu-PP-F11N短时输注,间隔约4周,分别用与不用Entresto®预处理。
- Entresto®单次口服,含48.6 mg沙库巴曲;对不良事件分级,并行定量SPECT/CT和采血,计算肿瘤与相关器官吸收剂量。
主要发现
- Entresto®预处理未显示额外毒性,并显著提高[177Lu]Lu-PP-FF11N在血液中的稳定性(p<0.001)。
- Entresto®预处理后肿瘤吸收剂量中位数为0.74 Gy/GBq,未预处理为0.28 Gy/GBq,预处理后高2.6倍(P=0.03)。
- 同时观察到胃、肾和骨髓吸收剂量增加,用与不用Entresto®时肿瘤与器官吸收剂量比无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A new generation of radiolabeled minigastrin analogs delivers low radiation doses to kidneys and are considered relatively stable due to less enzymatic degradation. Nevertheless, relatively low tumor radiation doses in patients indicate limited stability in humans. We aimed at evaluating the effect of sacubitril, an inhibitor of the neutral endopeptidase 1, on the stability and absorbed doses to tumors and organs by the cholecystokinin-2 receptor agonist [177Lu]Lu-PP-F11N in patients. In this prospective phase 0 study eight consecutive patients with advanced medullary thyroid carcinoma and a current somatostatin receptor subtype 2 PET/CT scan were included. Patients received two short infusions of ~ 1 GBq [177Lu]Lu-PP-F11N in an interval of ~ 4 weeks with and without Entresto® pretreatment in an open-label, randomized cross-over order. Entresto® was given at a single oral dose, containing 48.6 mg sacubitril. Adverse events were graded and quantitative SPECT/CT and blood sampling were performed. Absorbed doses to tumors and relevant organs were calculated. RESULTS: Pretreatment with Entresto® showed no additional toxicity and increased the stability of [177Lu]Lu-PP-FF11N in blood significantly (p < 0.001). Median tumor-absorbed doses were 2.6-fold higher after Entresto® pretreatment (0.74 vs. 0.28 Gy/GBq, P = 0.03). At the same time, an increase of absorbed doses to stomach, kidneys and bone marrow was observed, resulting in a tumor-to-organ absorbed dose ratio not significantly different with and without Entresto®. CONCLUSIONS: Premedication with Entresto® results in a relevant stabilization of [177Lu]Lu-PP-FF11N and consecutively increases radiation doses in tumors and organs. Trial registration clinicaltrails.gov, NCT03647657. Registered 20 August 2018.
引用
- Rottenburger C, Hentschel M, Fürstner M, et al. In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study. EJNMMI Res. 2024. PMID: 38581480. doi:10.1186/s13550-024-01101-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。